Trial Profile

Safety and Efficacy Study of Pembrolizumab in Combination With LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant as Neoadjuvant TherapY——PLENTY Randomized Clinical Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2023 Results (n=22) assessing whether programmed death receptor 1 (PD-1) blockadeplus lenvatinib as a neoadjuvant therapy before LT allows safelyadministered and effectively reduces post-LT recurrence for those patients with hepatocellular carcinoma beyond Milan criteria presented at the European Association for the Study of the Liver Congress 2023
12 Aug 2020 Status changed from active, no longer recruiting to recruiting.
06 Aug 2020 Planned number of patients changed from 220 to 192.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com